Entropy Neurodynamics Limited (AU:ENP) — Market Cap & Net Worth
Market Cap & Net Worth: Entropy Neurodynamics Limited (ENP)
Entropy Neurodynamics Limited (AU:ENP) has a market capitalization of $34.64 Million (AU$48.95 Million) as of June 21, 2026. Listed on the AU stock exchange, this Australia-based company holds position #23291 globally and #880 in its home market, demonstrating a -3.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Entropy Neurodynamics Limited's stock price AU$0.03 by its total outstanding shares 1631826878 (1.63 Billion). Review Entropy Neurodynamics Limited (ENP) financial obligations to assess the company's total debt and financial obligations.
Entropy Neurodynamics Limited Market Cap History: 2025 to 2026
Entropy Neurodynamics Limited's market capitalization history from 2025 to 2026. Data shows growth from $38.10 Million to $34.64 Million (0.00% CAGR).
Entropy Neurodynamics Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Entropy Neurodynamics Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
24.00x
Entropy Neurodynamics Limited's market cap is 24.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $38.10 Million | $1.59 Million | -$5.33 Million | 24.00x | N/A |
Competitor Companies of ENP by Market Capitalization
Companies near Entropy Neurodynamics Limited in the global market cap rankings as of June 21, 2026.
Key companies related to Entropy Neurodynamics Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Entropy Neurodynamics Limited Historical Marketcap From 2025 to 2026
Between 2025 and today, Entropy Neurodynamics Limited's market cap moved from $38.10 Million to $ 34.64 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$34.64 Million | -9.09% |
| 2025 | AU$38.10 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Entropy Neurodynamics Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $34.64 Million USD |
| MoneyControl | $34.64 Million USD |
| MarketWatch | $34.64 Million USD |
| marketcap.company | $34.64 Million USD |
| Reuters | $34.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more